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ABSTRACT
Objective We investigated the contribution of small 
vessel disease (SVD) to anticoagulant- associated 
intracerebral haemorrhage (ICH).
Methods Clinical Relevance of Microbleeds in Stroke-2 
comprised two independent multicentre observation 
studies: first, a cross- sectional study of patients with 
ICH; and second, a prospective study of patients taking 
anticoagulants for atrial fibrillation (AF) after cerebral 
ischaemia. In patients with ICH, we compared SVD 
markers on CT and MRI according to prior anticoagulant 
therapy. In patients with AF and cerebral ischaemia 
treated with anticoagulants, we compared the rates of 
ICH and ischaemic stroke according to SVD burden score 
during 2 years follow- up.
Results We included 1030 patients with ICH (421 on 
anticoagulants), and 1447 patients with AF and cerebral 
ischaemia. Medium- to- high severity SVD was more 
prevalent in patients with anticoagulant- associated ICH 
(CT 56.1%, MRI 78.7%) than in those without prior 
anticoagulant therapy (CT 43.5%, p<0.001; MRI 64.5%, 
p=0.072). Leukoaraiosis and atrophy were more frequent 
and severe in ICH associated with prior anticoagulation. 
In the cerebral ischaemia cohort (779 with SVD), during 
3366 patient- years of follow- up the rate of ICH was 
0.56%/year (IQR 0.27–1.03) in patients with SVD, and 
0.06%/year (IQR 0.00–0.35) in those without (p=0.001); 
ICH was independently associated with severity of 
SVD (HR 5.0, 95% CI 1.9 to 12.2,p=0.001), and was 
predicted by models including SVD (c- index 0.75, 95% CI 
0.63 to 0.85).
Conclusions Medium- to- high severity SVD is 
associated with ICH occurring on anticoagulants, and 
independently predicts ICH in patients with AF taking 
anticoagulants; its absence identifies patients at low 
risk of ICH. Findings from these two complementary 
studies suggest that SVD is a contributory factor in 
ICH in patients taking anticoagulants and suggest that 
anticoagulation alone should no longer be regarded as a 
sufficient ’cause’ of ICH.
Trial registration NCT02513316
INTRODUCTION
Cerebral small vessel disease (SVD) accounts for the 
vast majority of non- traumatic spontaneous intrace-
rebral haemorrhage (ICH), accounting for 77% in 
patients aged 70 years or younger in a study from 
Western Europe1 and 77%–85% of patients aged 18 
years or older in a study from Western Europe and 
the USA.2 Meta- analyses3 of randomised controlled 
trials suggest that oral anticoagulants—vitamin K 
antagonists and direct oral anticoagulants (apix-
aban, dabigatran, edoxaban and rivaroxaban)—are 
a risk factor for ICH. However, there is no evidence 
that anticoagulants can cause arterial rupture, 
vascular fragility or inhibit vascular repair.4 5 In the 
context of many competing risk factors,6 7 the direct 
independent contribution of anticoagulation to 
ICH is unknown. Moreover, most ICHs on vitamin 
K antagonists occur within the therapeutic range8 
and a recent study found that patients with ICH 
while taking rivaroxaban had low plasma levels.9 
Despite these observations, oral anticoagulation is 
often regarded as a sufficient cause of ICH and has 
been used in clinical and mechanistic classification 
systems for ICH aetiology.10–12 Alternatively, it has 
been hypothesised that anticoagulation might exac-
erbate spontaneous ‘microbleeding’ due to SVD, 
resulting in symptomatic ICH.13–15
Several markers of SVD can be identified on 
neuroimaging.16 On MRI, cerebral microbleeds, 
cortical superficial siderosis, perivascular spaces, 
white matter hyperintensities, lacunes and atrophy 
can be diagnosed. On CT, leukoaraiosis, lacunes 
and atrophy can be measured. The overall burden 
of SVD can thus be assessed using scores based on 
MRI17 18 (presence of cerebral microbleeds, basal 
ganglia perivascular spaces, white matter hyperin-
tensities and lacunes) or CT (presence of leukoarai-
osis, lacunes and atrophy).
We hypothesised that cerebral SVD (causing brain 
small vessel fragility) is an important underlying 
contributory factor in ICH occurring in patients 
taking oral anticoagulants. Thus, SVD should: 
(1) be highly prevalent and associated with prior 
anticoagulant use in cross- sectional analyses of 
patients with ICH; and (2) predict ICH in prospec-
tive analyses of patients without ICH treated with 
oral anticoagulants. Moreover, if SVD is necessary 
for anticoagulant- associated ICH, then patients 
without any evidence of SVD prior to starting oral 
anticoagulation should have a very low rate of 
subsequent ICH.
With these considerations in mind, we anal-
ysed data from two independent cohorts to obtain 
complementary lines of evidence for a causal link 
between SVD and anticoagulant- related ICH 
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through strength of association, consistency, biological gradient, 
temporality and coherence as described in the Bradford Hill 
criteria.19 We aimed to determine: (1) the association of SVD 
burden at baseline with future risk of ICH and ischaemic stroke 
in patients with atrial fibrillation (AF) exposed to oral antico-
agulants for the first time; and (2) the prevalence and severity 
of SVD markers on CT and MRI and the overall SVD burden 
in patients with ICH on prior anticoagulant therapy compared 
with patients with ICH without prior anticoagulant therapy.
MATERIAL AND METHODS
Study design and participants
The prospective observational ‘Clinical Relevance of Microbleeds 
in Stroke’ (CROMIS-2) Study enrolled adult patients (ie ≥18 
years of age) at 79 centres in the UK and 1 centre in the Neth-
erlands into two studies. In brief, in study 1 (‘atrial fibrillation 
cohort’) patients with presumed cardioembolic ischaemic stroke 
due to non- valvular AF started on oral anticoagulant therapy 
for secondary stroke prevention were enrolled into an incep-
tion cohort study with follow- up for ischaemic stroke and intra-
cranial haemorrhage. We excluded patients if they could not 
undergo MRI at baseline, had a defined contraindication to oral 
anticoagulation therapy or had previously received therapeutic 
anticoagulation. In study 2 (‘intracerebral haemorrhage cohort’) 
we enrolled patients with imaging- confirmed non- traumatic 
ICH with or without treatment with oral anticoagulants (for any 
indication including AF) prior to onset. The trial protocol20 and 
the main analysis13 of study 1 (AF cohort) have been published 
previously. The current analysis follows a prespecified analysis 
plan (V.1.1 dated 31 October 2018 and approved by the Trial 
Steering Committee) using data from both substudies in a two- 
step analysis. Exclusion criteria included known underlying 
structural cause for ICH or major head trauma (causing loss of 
consciousness and thought to be sufficient to have caused the 
ICH) in the last 24 hours before presentation.
Patients with capacity gave informed written consent. When 
patients could not consent, we obtained written informed 
consent from a proxy as defined by relevant local legislation.
Procedures
In study 1 (AF cohort) all patients underwent baseline brain 
MRI according to a predefined protocol parameter range,20 
designed to detect relevant markers of cerebrovascular disease 
which required T2*-weighted gradient- recalled echo, axial 
T1- weighted, axial T2- weighted, coronal fluid- attenuated inver-
sion recovery (FLAIR), and diffusion- weighted imaging with 
apparent diffusion coefficient maps. In study 2 (ICH cohort), all 
patients had intracranial haemorrhage confirmed on acute base-
line non- contrast brain CT according to local standard clinical 
protocols; a subgroup of patients underwent additional brain 
MRI (‘intracerebral haemorrhage MRI subgroup’). We collected 
anonymised DICOM images of all patients at the core imaging 
analysis centre (Stroke Research Centre, UCL Queen Square 
Institute of Neurology). Imaging analysis of SVD markers on CT 
(ICH cohort) and MRI (AF cohort and ICH MRI subgroup) was 
performed by clinical research fellows (DW, GB and DJS) trained 
by a professor of neuroradiology (HRJ) according to an inter-
national consensus statement16 using validated scales and scores 
where available21–27 and as described in prior research.13 28 Raters 
were blinded to anticoagulation therapy status of the patients.
The following SVD markers were analysed: lacunes were 
identified and counted on axial non- contrast CT scans and on 
T2/FLAIR MRI sequences. Cerebral microbleeds were rated 
using blood- sensitive sequences and the validated Microbleed 
Anatomical Rating Scale.25 Cortical superficial siderosis was 
identified on blood- sensitive sequences and classified as either 
focal (involving ≤3 sulci) or disseminated (involving ≥4 sulci).29 
White matter hyperintensities were rated on MRI T2/FLAIR in 
deep white matter and periventricular white matter sequences 
using the Fazekas Scale.24 30 Leukoaraiosis on CT was rated 
using the Van Swieten Scale in the anterior (plexus choroi-
deus and cella media) and posterior (cella media and centrum 
semiovale) regions.21 Global cortical atrophy was rated using 
the Pasquier Scale on axial MRI T1/FLAIR images (T2 in the 
absence of FLAIR).23 Medial temporal lobe atrophy was rated 
using the Scheltens Visual Scale26 on MRI T1 or FLAIR coronal 
images. For both, the hemisphere contralateral to the intrace-
rebral haemorrage was preferentially rated. Deep and cortical 
atrophy on CT was rated using a visual scale.31 32 MRI- visible 
perivascular spaces in the centrum semiovale and basal ganglia 
were defined and rated on T2/FLAIR sequences using a validated 
4- point visual rating scale.27 33
The burden of SVD on MRI was rated using a validated SVD 
burden score with an ordinal scale from 0 to 4 by counting the 
presence of MRI features of SVD. One point is awarded for 
each of the following: presence of ≥1 lacunes and ≥1 cerebral 
microbleeds (1 point each if present), presence of perivascular 
spaces in the basal ganglia (grade 2–4 according to a previously 
published scale,27 1 point if present) and presence of white 
matter hyperintensities (confluent deep white matter hyperin-
tensities Fazekas Score 2 or 3 or irregular periventricular white 
matter hyperintensities extending into the deep white matter 
Fazekas Score 3; 1 point if present). The SVD burden score was 
categorised into SVD burden absent/below imaging detection 
level (score of 0) versus present (score of 1–4). Severity of the 
SVD burden was further categorised as none/low (score of 0), 
medium (score 1–2) and high (score of 3–4). Additionally, in 
the ICH cohort, the SVD burden was rated using a previously 
described CT- based burden score (using leukoaraiosis, lacunes 
and atrophy; score range 0–3)32 and similarly categorised into 
none/low burden (CT score of 0), medium (CT score of 1) and 
high (CT score of 2–3).
Baseline clinical data including demographics, risk factors, 
concomitant medication and characteristics of baseline isch-
aemic stroke (AF cohort) or ICH (ICH cohort) were collected 
by local study personnel using standardised forms as described 
in prior research.13 34 We calculated the CHA2DS2- VASc Score 
(Congestive heart failure, Hypertension, Age ≥ 75 y, Diabetes 
mellitus, Stroke, Vascular disease, Age 65-74 y and Sex cate-
gory, to predict ischaemic stroke)35 and the HAS- BLED36 Score 
(Hypertension, Abnormal renal/liver function, Age >= 65 years, 
Stroke, Bleeding, Labile INRs, Taking other drugs, Alcohol 
intake; to predict ICH) from clinical variables. In the AF cohort, 
follow- up information was obtained from patients and general 
practitioners at 6, 12 and 24 months via standardised structured 
postal questionnaires or telephone interviews.
Outcomes
In the ICH cohort, the main variable of interest was prevalence 
and severity of SVD markers at ICH onset on CT (leukoarai-
osis, lacunes and atrophy—summarised using the burden score). 
Secondary outcomes were prevalence and severity of SVD 
markers on MRI (cerebral microbleeds, cortical superficial sider-
osis, perivascular spaces, white matter hyerintensities, lacunes 
and atrophy) and the overall MRI SVD burden score (presence 
and severity as defined above).
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In the AF cohort, the primary outcome was symptomatic ICH 
(defined as bleeding in the brain parenchyma, not including 
haemorrhage exclusively in subarachnoid or subdural spaces) 
confirmed on brain imaging during follow- up. Secondary 
outcome was ischaemic stroke confirmed on brain imaging 
during follow- up.
Primary and secondary outcome events in the AF cohort were 
adjudicated by a board of two professors of vascular neurology 
(DJW and MMB) and a clinical research fellow (DW). All adju-
dication was blinded to baseline MRI SVD burden. In cases of 
disagreement, we reached consensus after discussion.
Statistics
The statistical analysis (DJS and GA) was conducted following a 
preplanned statistical analysis plan approved by the trial steering 
committee (V.1.1 dated 31 October 2018, not published). We 
conducted a two- stage analysis: in stage 1, (ICH cohort), we 
determined the presence and severity of SVD markers on CT and 
MRI and analysed their association with the type of ICH (with 
or without prior use of oral anticoagulants). Finally, we deter-
mined and compared the overall SVD burden using MRI among 
different types of ICH; in stage 2 (AF cohort), we compared the 
rate of ICH and ischaemic stroke during follow- up in patients 
with SVD burden on baseline MRI (MRI burden score of 1–4) 
and those free of SVD burden on baseline MRI (MRI burden 
score of 0). In the secondary analysis we compared the rate of 
ICH according to SVD burden severity (MRI burden score of 
0=none/low burden; score of 1–2=medium burden; score of 
3–4=igh burden).
In the ICH cohort, we divided patients into two groups: (1) 
Patients with intake of oral anticoagulants prior to onset of ICH 
(anticoagulant- associated ICH); and (2) Patients without prior 
intake oral anticoagulants. We compared demographic and clin-
ical baseline characteristics among groups within both cohorts 
using Fisher’s/Pearson χ2 test for categorical variables and the 
t- test/Mann- Whitney U test for continuous variables as appro-
priate. We described prevalence and severity of SVD markers 
on CT and MRI using descriptive statistics, Pearson χ2 test and 
appropriate graphs. We compared prevalence, distribution and 
mean value of the SVD burden score using descriptive statistics, 
Fisher’s/Pearson χ2 test and graphs as appropriate. We assessed 
the association of prior oral anticoagulation therapy (vs non- 
prior anticoagulation therapy) and MRI- SVD burden score 
using univariable and multivariable logistic regression models 
adjusting for predefined variables. We assessed the association 
between prior anticoagulation (vs no prior anticoagulation) 
and SVD markers on CT and MRI using univariable and multi-
variate analysis adjusting for predefined variables. For SVD 
markers on CT, we adjusted our between- group comparisons 
for the following predefined variables because of their associ-
ation with cerebrovascular disease including SVD: age, history 
of ischaemic stroke, history of ICH, AF, myocardial infarction, 
diabetes mellitus, hypertension, hypercholesterolaemia, current 
smoking and concomitant medication with antiplatelets agents, 
antihypertensive agents and statins. Due to a smaller sample size, 
we used only the following predefined variables for multivariate 
analysis of the SVD markers on MRI and the MRI SVD burden 
score: age, hypertension, diabetes mellitus, AF, hypercholestero-
laemia, current smoking and antihypertensive treatment. We 
present ORs with 95% CIs for all models.
In the AF cohort, we divided patients into groups according to 
SVD burden severity: none/low SVD burden (MRI burden score 
of 0), medium SVD burden (MRI burden score of 1–2) or high 
SVD burden (MRI burden score of 3–4). We compared baseline 
demographics and risk factor profiles between the aforemen-
tioned SVD burden groups. We calculated annualised event rates 
for ICH and ischaemic stroke in the different groups (observed 
events/patient- years of follow- up). We estimated Kaplan- Meier 
curves according to SVD burden groups. The association between 
severity of SVD burden with ICH and ischaemic stroke during 
follow- up was analysed using Cox proportional hazards models. 
We constructed univariable and two multivariable models to 
predict ICH: multivariable model 1 included the HAS- BLED36 
Score (a score estimating the 1- year risk of major bleeding in 
patients with AF using clinical risk factors and demographics) 
which was dichotomised in two categories: low risk (score 0–2) 
and high risk (score ≥3). For ischaemic stroke as outcome, we 
used the CHA2DS2- VASc
35 Score (a score estimating the risk 
of systemic embolism) dichotomised at the median (5) of our 
cohort into medium (score of 2–4) and high (score of ≥5) risk. 
Multivariable model 2 included age and history of hypertension. 
We calculated HRs and 95% CI. We investigated the predic-
tive ability of SVD burden using a Cox model and performed 
internal validation using bootstrapping and assessed the calibra-
tion and discrimination of this model. All statistical analysis was 
conducted using STATA V.15.0. This study is registered with 
ClinicalTrials. gov, number NCT02513316.
Role of the funding source
Neither the funders nor the sponsor had input into study design; 
data collection, data analysis, data interpretation; writing of 
the report; or the decision to submit the paper for publication. 
The corresponding author had full access to all the data in the 
study and had final responsibility for the decision to submit for 
publication.
Data availability
Anonymised data are available on request from the corre-
sponding author for any reasonable request and after clearance 
by the competent ethics committee.
RESULTS
We included 1030 patients in the ICH cohort and 1447 patients 
in the AF cohort. Figure 1 displays the study flow chart.
Figure 1 Study flow chart. AF, atrialfibrillation; CROMIS-2, Clinical 
Relevance of Microbleedsin Stroke; ICH, intracerebral haemorrhage; SVD, 
small vessel disease; OAC, oral anticoagulation.
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ICH cohort—baseline characteristics
In the ICH cohort, among 1030 patients, 421 patients had 
ICH with prior oral anticoagulant therapy (40.9%) and 609 
patients had ICH without prior anticoagulant therapy (59.1%). 
The median age of the ICH cohort was 76 years (IQR 66–83 
years), the median haematoma volume 7 mL (IQR 2–18 mL) and 
439 patients (42.6%) were female. Among the 421 patients on 
prior anticoagulation, 28 patients (6.7%) were taking direct oral 
anticoagulants (dabigatran, rivaroxaban or apixaban). All other 
patients were taking vitamin K antagonists. Among the entire 
cohort, 236 patients (on prior anticoagulant therapy: 61 patients 
and without prior anticoagulant therapy: 175 patients) had addi-
tional MRI available (MRI substudy cohort).
Table 1 displays the baseline characteristics of patients in the 
ICH cohort. Patients on prior anticoagulation therapy were 
significantly older and had more cerebrovascular risk factors (ie, 
history of ischaemic stroke, AF, hypertension, hypercholesteri-
naemia and diabetes mellitus) while patients without prior anti-
coagulation therapy were more often current smokers. Baseline 
haemorrhage volume, National institute of health stroke score 
(NIHSS) and Glasgow coma scale (GCS) were similar in both 
groups. Haematoma location was less often deep (prior antico-
agulation: 188 patients/44.7% vs no prior anticoagulation: 337 
patients/55.3%) and more often lobar (prior anticoagulation: 175 
patients/41.6% vs no prior anticoagulation 230 patients/33.8%) 
and cerebellar (prior anticoagulation: 35 patients/8.3% vs no 
prior anticoagulation 23 patients/3.8%, p<0.001 for haemor-
rhage location) in patients on prior anticoagulation. Intraven-
tricular haemorrhage was more often in patients with prior 
anticoagulation therapy (112 patients, 26.6%) compared with 
without prior anticoagulation therapy (100 patients, 16.4%, 
p<0.001). Overall, patients with deep haemorrhage had more 
often intraventricular expansion (n=141, 26.9%) compared to 
patients with lobar haemorrhage (n=54, 13.3%).
Prevalence and severity of SVD markers among patients with 
intracerebral haemorrhage and prior oral anticoagulation 
therapy
The prevalence of medium- to- high severity SVD on CT and 
MRI was higher in those taking prior anticoagulants: on CT, a 
medium- to- high burden of SVD (measured using the CT burden 
score32 was present in 236 of 421 patients with prior anticoag-
ulant therapy (56.1%) and 265 of 609 patients without prior 
anticoagulant therapy (43.9%, p<0.001, figure 2)). On MRI, a 
medium- to- high burden of SVD (measured using the MRI burden 
score18 was present in 48 of 61 patients with prior anticoagulant 
therapy (78.7%) and 114 of 169 patients without prior anti-
coagulant therapy (64.5%, p=0.072, figure 2)). In univariable 
analyses, prior anticoagulant therapy was significantly associated 
with higher SVD burden (unadjusted OR 1.5, 95% CI 1.1 to 1.9, 
p=0.007), but not after adjusting for confounders (adjusted OR 
1.2, 95% CI 0.7 to 2.0, p=0.436). A post hoc sensitivity analysis 
among patients with deep haemorrhage confirmed this finding 
(adjusted OR: 0.99; 95% CI 0.51 to 1.91). Among patients on 
vitamin- K antagonist treatment with available international 
normalized ratio (INR) at haemorrhage onset (n=388 of 393 
patients, 98.7%), the percentage of patients with medium- to- 
high SVD burden on CT was 60.6% among patients with INR 
<2.0, 48.2% among patients with INR 2.0–3.0 and 49.2% 
among patients with INR >3.0 (p=0.2).
Leukoaraiosis (on CT) and white matter lesions (on MRI), 
cortical atrophy on CT and MRI, and perivascular spaces in the 
basal ganglia were more prevalent and severe in patients with 
Table 1 Baseline characteristics of the intracerebral haemorrhage cohort (all patients with intracerebral haemorrhage, comparing patients taking 
oral anticoagulants prior to ICH onset with those patients not taking anticoagulants) and atrial fibrillation cohort (all patients with ischaemic stroke, 
atrial fibrillation and oral anticoagulant therapy comparing patients with none–low small vessel disease burden (small vessel disease absent) to 
those with medium–high small vessel disease burden (small vessel disease present))
















Age 79 (72–84) 72 (62–80) <0.001 80 (73–85) 73 (66–80) <0.001
Female sex 175 (41.6%) 264 (43.4%) 0.548 336 (43.1%) 275 (41.2%) 0.451
NIHSS on admission 6 (3–13) 8 (4–13) 0.115 4 (2–9) 5 (2–11) 0.169
GCS on admission 15 (14–15) 15 (14–15) 0.126 n/a n/a n/a
Haemorrhage volume in ml All locations 7.2 (2.4–20.6) 6.9 (2.1–16.0) 0.198 n/a n/a n/a
Deep location 5.5 (1.6–12.2) 4.4 (1.6–10.4) 0.237
Lobar location 17.5 (5.0–35.3) 15.0 (6.7–31.7) 0.760
INR on admission 2.3 (1.8–3.0) 1.0 (1.0–1.1) <0.001 n/a n/a n/a
Medical history
History of intracerebral haemorrhage 11 (2.6%) 32 (5.3%) 0.028 5 (0.7%) 3 (0.5%) 0.624
History of ischaemic stroke 75 (17.8%) 58 (9.5%) <0.001 99 (12.9%) 41 (6.3%) <0.001
Atrial fibrillation 326 (79.1%) 33 (6.1%) <0.001 779 (100%) 668 (100%) n/a
Hypertension 310 (73.6%) 372 (61.1%) <0.001 541 (71.1%) 365 (55.0%) <0.001
Myocardial infarction 51 (12.1%) 35 (5.8%) <0.001 87 (11.3%) 44 (6.6%) 0.002
Hypercholesterolaemia 212 (50.4%) 237 (38.9%) <0.001 344 (44.9%) 293 (44.4%) 0.853
Current smoker 24 (5.7%) 84 (13.8%) <0.001 79 (10.5%) 80 (12.2%) 0.587
Diabetes mellitus 99 (23.5%) 90 (14.8%) <0.001 135 (17.3%) 107 (16.1%) 0.521
Antiplatelet agent therapy 51 (12.1%) 208 (34.2%) <0.001 33 (5.2%) 43 (5.6%) 0.568
 on M
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prior anticoagulant therapy (table 2). There was no difference 
in lacunes (on either CT or MRI), perivascular spaces in the 
centrum semiovale, cerebral microbleeds, siderosis or medial 
temporal lobe atrophy (table 2). However, after adjusting for 
potential confounders, there were no statistically significant 
differences in any SVD marker on CT or MRI between patients 
with prior anticoagulant therapy and those without (table 3).
AF cohort—baseline characteristics
Among 1447 patients in the AF cohort, SVD was absent (burden 
score of 0) in 668 patients (46.2%) and present (burden score of 
1–4) in 779 patients (53.8%). Among those with SVD present, 
671 patients (86.1%) had medium burden (burden score 1–2) 
and 108 patients (13.9%) had high burden (burden score of 
3–4). The median age of the AF cohort was 77 years (IQR 69–83 
years) and 611 patients (42.2 %) were female. There was no 
difference regarding treatment with direct oral anticoagulants 
between both groups (SVD burden present: 281 (37.6%), SVD 
burden absent: 244 (37.4%), p=0.840).
Table 1 displays baseline characteristics of patients with SVD 
present compared with those with no markers of SVD on MRI 
(measured using the SVD burden score). Patients with SVD were 
older, had higher HAS- BLED (median HAS- BLED Score: SVD 
burden present 4, IQR 3–4 and SVD burden absent 3, IQR 3–4, 
p=0.004) and CHA2DS2- VASc (median CHA2DS2- VASc Score: 
SVD burden present 5, IQR 4–6 and SVD burden absent 5, IQR 
3–5, p<0.001) Scores and more often a history of ischaemic 
stroke, hypertension and myocardial infarction. Overall, 1210 
of 1447 patients (83.6%) in the AF cohort had a HAS- BLED 
Score of ≥3 (indicating high risk of bleeding).
During the follow- up of 3366 patient- years, there were 11 
ICHs and 56 ischaemic strokes. The annual rate of ICH was 
0.33%/year (95% CI 0.16% to 0.58%); the annualised rate of 
ischaemic stroke was 1.66%/year (95% CI 1.26% to 2.15%).
SVD burden and future risk of ICH
ICH was more frequent in patients with SVD (p<0.001) using 
the log- rank test for equality of survivor functions (figure 3A) 
and the annualised rate increased with SVD severity (table 4). 
The severity of SVD burden was associated with ICH in univari-
able regression analysis (HR 4.8, 95% CI 1.9 to 12.0, p=0.001) 
which was maintained in multivariable analysis adjusting for 
HAS- BLED Score (HR 5.0, 95% CI 1.9 to 12.2, p=0.001) or for 
age and hypertension (HR 4.6, 95% CI 1.8 to 11.8, p=0.001).
By contrast, using the HAS- BLED Score (data available in 
1279 patients, 87.7%, figure 3B), there was no statistically 
significant difference between patients with a HAS- BLED Score 
of ≥3 indicating high risk of bleeding (n=1110 patients, 2589 
patient- years of follow- up, 9 ICH during follow- up, annual-
ised rate 0.35%/year, 95% CI 0.16 to 0.66) compared with 
patients with a HAS- BLED Score of <3 indicating a low risk of 
bleeding (n=169, 386 patient- years of follow- up, 1 ICH during 
follow- up, annualised rate 0.26%/year, 95% CI 0.01 to 1.44).
Recurrent ischaemic stroke was more frequent in patients with 
SVD (p=0.015) using the log- rank test (figure 3C). The severity 
of SVD burden was associated with recurrent ischaemic stroke 
in univariable (p=0.01, table 4) analysis. In multivariable anal-
ysis adjusting for the CHA2DS2- VASc Score (p=0.049) or age 
and hypertension (p=0.075), there was weak evidence for an 
increased risk of recurrent ischaemic stroke. Using the CHA2DS2- 
VASc Score (data available in 1409 patients=95.4%, figure 3D), 
the risk of recurrent ischaemic stroke was more frequent in 
patients with a score of ≥5 indicating high risk (n=872, 1899 
patient- years of follow- up, 47 recurrent ischaemic strokes, 
annualised rate 2.42%/year, 95% CI 1.80 to 3.18) compared 
with those with a score of 2–4 indicating medium risk (n=537, 
8 recurrent ischaemic strokes, 1334 patient- years of follow- up, 
annualised rate 0.60%/year, 95% CI 0.28 to 1.14).
After adjusting for optimism, the c- index for the unadjusted 
model for ICH using severity of SVD burden (c- index: 0.75, 
95% CI 0.63 to 0.85) was higher than a model using the HAS- 
BLED Score (c- index: 0.51, 95% CI 0.39 to 0.57). Multivariable 
models including severity of SVD burden and the HAS- BLED 
Score (model 1; c- index: 0.73, 95% CI 0.64 to 0.86) or age and 
hypertension (model 2; c- index: 0.71, 95% CI 0.63 to 0.84) did 
not further improve prediction of ICH (all p>0.05). The unad-
justed model exhibited the best calibration (calibration slope 
near to 1).
DISCUSSION
We show that: (1) imaging markers of SVD are highly prevalent 
and severe in patients with ICH both with and without prior 
anticoagulant therapy, but are more common in those with 
ICH associated with anticoagulation; (2) the severity of SVD 
(measured with a four- item MRI score) independently predicts 
ICH in patients with AF taking anticoagulants; (3) the absence of 
SVD identifies patients at very low risk of ICH on anticoagulant 
therapy; and (4) prediction models for ICH including severity 
Figure 2 Small vessel disease burden on MRI in patients with 
intracerebral haemorrhage (ICH) with prior anticoagulation therapy 
compared with those without prior anticoagulation therapy.
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Table 2 Distribution of different markers of small vessel disease on CT and MRI in patients with intracerebral haemorrhage comparing patients 
with prior anticoagulation therapy and those without
CT cohort
Prior anticoagulation therapy (n=421) No prior anticoagulation therapy (n=609) P value
Leukoaraiosis (van Swieten Score)
Anterior region 0 221 (52.5%) 365 (59.9%) 0.059
1 120 (28.5%) 149 (24.5%)
2 80 (19.0%) 95 (15.6%)
Posterior region 0 223 (53.0%) 373 (61.2%) 0.023
1 77 (18.3%) 84 (13.8%)
2 121 (28.7%) 152 (25.0%)
Lacunes
Number of lacunes None 385 (91.5%) 545 (89.5%) 0.373
1 lacuna 25 (5.9%) 50 (8.2%)
≥1 lacunes 11 (2.6%) 14 (2.3%)
Atrophy
Cortical atrophy Absent 25 (5.9%) 137 (22.5%) <0.001
Moderate 299 (71.0%) 371 (60.9%)
Severe 97 (23.0%) 101 (16.6%)
Deep atrophy Absent 76 (18.1%) 190 (31.2%) <0.001
Moderate 228 (54.2%) 302 (49.6%)
Severe 117 (27.8%) 117 (19.2%)
MRI cohort
  Prior anticoagulation therapy (n=61) No prior anticoagulation therapy (n=175)
White matter hyperintensities (Fazekas Scale)
Periventricular white matter 0 1 (1.6%) 12 (7.1%) 0.065
1 19 (31.2%) 73 (43.2%)
2 28 (45.9%) 63 (37.3%)
3 12 (21.3%) 21 (12.4%)
Deep white matter 0 19 (31.2) 85 (50.3%) 0.008
1 16 (26.3%) 38 (22.5%)
2 14 (23.0%) 35 (20.7%)
3 12 (19.7%) 11 (6.5%)
Lacunes
Number of lacunes No 46 (79.3%) 124 (77.0%) 0.862
1 8 (13.8%) 27 (16.8%)
≥2 4 (6.9%) 10 (6.2%)
Atrophy
Global cortical atrophy Absent 19 (31.2%) 99 (57.9%) 0.001
Moderate 30 (49.2%) 48 (28.1%)
Severe 12 (19.7%) 24 (14.0%)
Medial temporal atrophy Absent 10 (21.7%) 38 (27.3%) 0.429
Moderate 20 (43.5%) 66 (47.5%)
Severe 16 (34.8%) 35 (25.2%)
Cerebral microbleeds
Number None 26 (42.6%) 94 (53.7%) 0.326
1 7 (11.5%) 17 (9.7%)
≥2 28 (45.9%) 64 (36.6%)
Cortical superficial siderosis
None 45 (88.2%) 134 (90.5%) 0.889
Focal 4 (7.8%) 9 (6.1%)
Disseminated 2 (3.9%) 5 (3.4%)
Perivascular spaces
Centrum semiovale None 5 (8.2%) 14 (8.2%) 0.928
Moderate 31 (50.8%) 91 (53.5%)
Severe 25 (41.0%) 65 (38.2%)
Basal ganglia None 7 (11.5%) 27 (15.9%) 0.001
Moderate 37 (60.7%) 128 (75.3%)
Severe 17 (27.9%) 15 (8.8%)
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of SVD burden have good discrimination, but a commonly used 
clinical score (HAS- BLED) performs poorly.
Our findings confirm and expand current knowledge on 
the role of SVD in ICH in patients taking anticoagulants, and 
strongly suggest SVD as an important contributory cause of ICH 
in these patients. This study is the first to compare the burden of 
SVD markers among patients with ICH with and without prior 
anticoagulation therapy. The majority of patients who had ICH 
with prior anticoagulant therapy had SVD burden detectable 
on CT (56.1%) or MRI (78.7%). Moreover, medium- to- high 
severity SVD was more prevalent in patients with anticoagulant- 
associated ICH (CT 56.1%, MRI 78.7%) than in those without 
prior anticoagulant therapy (CT 43.5%, p<0.001; MRI 64.5%, 
p=0.072). Since SVD is the commonest cause of spontaneous 
ICH overall, our findings are consistent with the hypothesis that 
SVD is contributory or causal for ICH occurring during antico-
agulant therapy. We can only speculate about the possible aeti-
ology in those patients without SVD burden. However, on MRI, 
there were subtle signs of SVD present in all but two patients 
which did not reach the level to score one point on the respec-
tive burden score scale (eg, Fazekas grade I), so SVD is likely to 
be contributory or causal in these patients, too. A recent meta- 
analysis found haematoma location—as a surrogate marker for 
underlying type of SVD (cerebral amyloid angiopathy or hyper-
tensive deep perforator arteriolopathy)—to be more frequently 
cerebellar and intraventricular in ICH associated with the use of 
anticoagulants37 possibly reflecting differences in the spectrum 
of underlying type of SVD. We systematically assessed prev-
alence, severity and burden of SVD lesions, but future studies 
are needed to determine whether the spectrum of SVD (ie, deep 
perforator arteriolopathy vs cerebral amyloid angiopathy) differs 
between patients with ICH and prior anticoagulant therapy and 
those without.
Recent data from CROMIS-213 38 found that cerebral 
microbleeds—a key haemorrhagic imaging marker of SVD—
are associated with a risk of ICH in patients taking anticoag-
ulant therapy. However, cerebral microbleeds alone could not 
explain all ICHs occurring during follow- up. Our current anal-
ysis builds on these previous findings by incorporating a full 
range of ischaemic and haemorrhagic SVD imaging markers 
(which are considered to share similar pathophysiological mech-
anisms16 39) combined in an SVD burden score. In our AF cohort, 
within 2 years of follow- up, ICH occurred almost exclusively 
in patients with medium or high SVD burden present on base-
line MRI, highlighting the importance of SVD as a risk marker 
(and furthermore, almost a necessary factor) for ICH. Only one 
patient had ICH in the group classified as having none or low 
SVD burden on baseline MRI, though this patient did have white 
matter lesions and enlarged perivascular spaces not fulfilling 
the criteria to score one point on the SVD burden score. In 
the absence of follow- up MRI in this patient, it is possible that 
SVD progressed during the 24- month observation period. We 
observed an increased ischaemic stroke risk with increasing SVD 
burden, suggesting that this may contribute to ischaemic stroke 
recurrence.
A major strength of our approach when compared with clin-
ical risk factor- based scores, such as HAS- BLED, is that we 
directly visualised the SVD lesions that are hypothesised to cause 
most spontaneous ICH. In our AF cohort, according to clinical 
risk factors and the HAS- BLED Score, 84% of the patients were 
at high risk (a score of 3 or higher). Using the severity of SVD 
burden provided higher precision predicting ICH compared 
with clinical risk factors.
Our study has the following strengths: we undertook two 
prospective multicentre studies with different designs which 
provide complementary and generalisable evidence for a causal 
link between SVD and ICH in patients taking oral anticoagu-
lants (through strength of association, consistency, biological 
gradient, and temporality and coherence as described in the 
Bradford Hill criteria).19 Both studies comprised a large number 
of well- phenotyped patients enrolled in 79 centres across the UK 
(and one in the Netherlands).
Our study has potential limitations: (1) despite our detailed 
clinical and neuroimaging phenotyping, unmeasured factors (eg, 
Table 3 Unadjusted and adjusted odds ratios for small vessel disease markers on CT and MRI in patients with intracerebral haemorrhage and prior 
anticoagulation therapy (vs no prior anticoagulation therapy)
Unadjusted OR P value Adjusted* OR P value
Leukoaraiosis/white matter lesions
CT Anterior region 1.2 (1.0–1.4) 0.023 0.8 (0.6–1.1) 0.209
Posterior region 1.2 (1.0–1.3) 0.038 0.8 (0.6–1.1) 0.234
MRI Periventricular white matter 1.7 (1.2–2.4) 0.003 1.2 (0.6–2.3) 0.656
Deep white matter 1.6 (1.2–2.1) 0.001 1.3 (0.8–2.2) 0.264
Lacunes
CT Any lacunes 0.8 (0.5–1.2) 0.274 1.0 (0.5–2.2) 0.948
MRI Any lacunes 1.5 (0.5–4.7) 0.451 0.6 (0.1–7.8) 0.666
Atrophy
CT Cortical atrophy 2.0 (1.6–2.5) <0.001 0.9 (0.6–1.4) 0.671
Deep atrophy 1.6 (1.3–1.9) <0.001 1.0 (0.7–1.5) 0.837
MRI Global cortical atrophy 1.7 (1.2–2.3) 0.004 0.6 (0.3–1.4) 0.267
Medial temporal lobe 1.2 (0.9–1.7) 0.200 0.7 (0.4–1.2) 0.187
Cerebral microbleeds, cortical superficial siderosis and perivascular spaces
MRI Perivascular spaces Centrum semiovale 0.9 (0.7–1.2) 0.567 1.2 (0.7–2.0) 0.589
Basal ganglia 2.0 (1.2–3.2) 0.006 1.5 (0.6–3.6) 0.393
Any cortical superficial siderosis 1.3 (0.4–4.2) 0.710 1.1 (0.1–1.7) 0.118
Any cerebral microbleeds 1.6 (0.9–2.8) 0.098 1.8 (0.6–5.0) 0.279
*All CT analysis were adjusted for age, history of ischaemic stroke, history of ICH, atrial fibrillation, myocardial infarction, diabetes mellitus, hypertension, hypercholesterolaemia, 
current smoking and concomitant medication with antiplatelet agents, antihypertensive agents and statins.
*All MRI analysis were adjusted for age, hypertension, diabetes mellitus, atrial fibrillation, hypercholesterolaemia, current smoking and antihypertensive treatment.
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genetic variants) might have influenced our results; (2) due to 
a relatively low rate of ICH in the AF cohort (n=11), we had 
limited statistical precision and power, so were unable to correct 
multivariable analysis for more than two co- variables; (3) both 
cohorts are likely to be affected by selection bias as participa-
tion in both studies required written informed consent, making 
it less likely that patients with very severe neurological deficits 
were enrolled (moreover, in the AF cohort, all patients had to 
have MRI and it is therefore likely that the index stroke was less 
severe); (4) in both studies, the vast majority of patients taking 
anticoagulants received vitamin K antagonist therapy and not 
all results may apply to patients taking direct oral anticoagu-
lants; (5) the ICH cohort was specifically designed to investi-
gate the characteristics of patients with ICH on anticoagulant 
therapy and enrolment of these patients was favoured to enrich 
the cohort, leading to a selection bias towards these patients; 
Figure 3 Kaplan- Meier curves of intracerebral haemorrhage (A, C) and recurrent ischaemic (B, D) stroke according to small vessel disease (SVD) burden 
(A, B), the HAS- BLED score (for intracerebral haemorrhage) (C) and the CHA2DS2- VASc (for recurrent ischaemic stroke) (D).
Table 4 Total events, annualised event rate and univariable and multivariable association of presence/absence and severity of small vessel disease 
(SVD) burden and intracerebral haemorrhage and recurrent ischaemic stroke
Follow- up 
time Events
Annual event rate in 
%/year
Univariable Multivariable 1* Multivariable 2




None/low (0) 1586 1 0.06 (0.00–0.35) 1 (ref) 1 (ref)
Medium (1–2) 1535 6 0.39 (0.14–0.85) 4.8 (1.9–12.0) 0.001 5.0 (1.9–12.2) 0.001 4.6 (1.8–11.8) 0.001




None/low (0) 1586 17 1.07 (0.63–1.71) 1 (ref) 1 (ref) 1 (ref)
Medium (1–2) 1535 32 2.08 (1.43–2.93) 1.7 (1.1–2.5) 0.010 1.5 (1.0–2.3) 0.049 1.5 (1.0–2.2) 0.075
High (3–4) 245 7 2.86 (1.16–5.80)
*Multivariate model 1: HAS- BLED Score dichotomised in two categories: low risk (score 0–2) and high risk (score ≥3) for intracerebral haemorrhage and for CHA2DS2- VASc Score 
dichotomised in two categories: medium risk (score 2–4) and high risk (≥5) for recurrent ischaemic stroke.
Multivariate model 2: age and history of hypertension.
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(6) among patients in the ICH cohort, those with MRI were 
younger and with less neurological severity; this probably led to 
an underestimation of the SVD burden; and (7) technical aspects 
including field strength and sequence type (SWI vs GRE) were 
heterogenous throughout study sites which is a source of bias 
regarding detection of cerebral microbleeds.40
Our study provides new evidence that SVD is an important 
cause of ICH among patients taking anticoagulants, and further 
advocates against the erroneous classification of anticoagulant 
use as a sufficient ‘cause’ of ICH. Future studies are needed to 
determine whether ICH in patients taking prior anticoagulant 
therapy is more closely associated with the main known types of 
sporadic cerebral SVD—hypertensive deep perforator arteriol-
opathy or cerebral amyloid angiopathy. Importantly, in patients 
with AF taking oral anticoagulant therapy, MRI might help to 
estimate the risk of ICH: the absence of SVD on MRI can poten-
tially reassure patients, carers and treating physicians of a very 
low risk of ICH. However, our data do not support withholding 
anticoagulant therapy in patients with AF and SVD burden on 
MRI as these patients are also at high risk of ischaemic stroke. 
Future research is needed to determine whether alternative 
treatments (eg, left atrial appendage closure) might be a safe and 
effective option in patients with AF and high SVD burden.
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